Amanda L. Bain
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Amanda L. Bain has a total of 102 co-authors. Here are the top co-authors by number of shared publications:
- Debottam Sinha
QIMR Berghofer Medical Research Institute
14 shared publications - Desmond Yip
Department of Medical Oncology, The Canberra Hospital, Garran, ACT, Australia
14 shared publications - Jane Esther Dahlstrom
School of Medicine and Psychology, Australian National University, Acton, ACT, 0200, Australia
14 shared publications - Laeeq Malik
Cancer Therapy and Research Center (CTRC), University of Texas Health Science Center, San Antonio, TX, USA.
14 shared publications - Sudha Rao
Gene Regulation and Translational Medicine Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Australia
14 shared publications - Amy Ives
16Department of Medical Oncology, Royal Brisbane and Women’s Hospital, Brisbane, Australia
13 shared publications
Latest Publications
- Open Access
- 14 November 2025
- Published by Springer Nature in Research Square
Essential role of single-stranded DNA-binding proteins Ssb1 and Ssb2 in maintaining intestinal epithelial homeostasis
Ssb1 and Ssb2 are single-stranded DNA-binding proteins with overlapping roles in genome stability. Both contain an OB-fold domain and interact with C9orf80 and IntS3, components of the Integrator complex which regulates snRNA processing, enhancer RNA biogenesis, and resolution of promoter-proximal RNA polymerase II (Pol II) pausing or early termination . We previously showed that combined loss of Ssb1 and Ssb2 leads to embryonic lethality or acute multi-organ failure in adult mice. Here, we show that intestine-specific deletion of both genes (DKO) causes severe radiomimetic damage to the intestinal proliferative crypt compartment, resulting in villous atrophy, marked malabsorption, and mortality, demonstrating that gut-specific mSSB loss is sufficient to drive systemic breakdown. An initial surge in intestinal progenitor cell proliferation preceded crypt depletion, suggesting transient regeneration followed by intestinal stem cell (ISC) exhaustion. DKO tissue failed to grow ex vivo , confirming a cell-autonomous requirement for mSsb2 in ISC maintenance. Mechanistically, mSSBs loss led to R-loop accumulation, p53 activation and interferon-stimulated gene expression, consistent with a failure to resolve transcription-associated genomic stress. Together, these findings uncover a critical, previously unrecognized role for Ssb1 and Ssb2 in regulating intestinal stem cell homeostasis and epithelial regeneration, with broad implications for gastrointestinal development, regeneration, and diseases such as cancer and inflammation.
- 14 November 2025
- Published by Springer Nature in Research Square
Open AccessEssential role of single-stranded DNA-binding proteins Ssb1 and Ssb2 in maintaining intestinal epithelial homeostasis
Ssb1 and Ssb2 are single-stranded DNA-binding proteins with overlapping roles in genome stability. Both contain an OB-fold domain and interact with C9orf80 and IntS3, components of the Integrator complex which regulates snRNA processing, enhancer RNA biogenesis, and resolution of promoter-proximal RNA polymerase II (Pol II) pausing or early termination . We previously showed that combined loss of Ssb1 and Ssb2 leads to embryonic lethality or acute multi-organ failure in adult mice. Here, we show that intestine-specific deletion of both genes (DKO) causes severe radiomimetic damage to the intestinal proliferative crypt compartment, resulting in villous atrophy, marked malabsorption, and mortality, demonstrating that gut-specific mSSB loss is sufficient to drive systemic breakdown. An initial surge in intestinal progenitor cell proliferation preceded crypt depletion, suggesting transient regeneration followed by intestinal stem cell (ISC) exhaustion. DKO tissue failed to grow ex vivo , confirming a cell-autonomous requirement for mSsb2 in ISC maintenance. Mechanistically, mSSBs loss led to R-loop accumulation, p53 activation and interferon-stimulated gene expression, consistent with a failure to resolve transcription-associated genomic stress. Together, these findings uncover a critical, previously unrecognized role for Ssb1 and Ssb2 in regulating intestinal stem cell homeostasis and epithelial regeneration, with broad implications for gastrointestinal development, regeneration, and diseases such as cancer and inflammation.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
Supplementary Table S1. List of the PI3K/mTOR inhibitors
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
Supplementary Table S1. List of the PI3K/mTOR inhibitors
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
Supplementary Table S3. Inhibition of human PI3K isoenzymes in vitro by paxalisib in fluorescence polarization biochemical assays.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
Supplementary Table S3. Inhibition of human PI3K isoenzymes in vitro by paxalisib in fluorescence polarization biochemical assays.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Methods from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
Supplementary Methods to accompany manuscript
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
Supplementary Methods to accompany manuscript
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Results from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
Supplementary Results to accompany manuscript
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Results from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
Supplementary Results to accompany manuscript
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
Supplementary Figure 3. NanoString nCounter analysis highlighting distinct gene expression profiles in Paxalisib-treated tumors.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
Supplementary Figure 3. NanoString nCounter analysis highlighting distinct gene expression profiles in Paxalisib-treated tumors.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
Supplementary Figure 7. Associations between PIK3R2 gene expression and survival probability amongst TNBC patient cohorts.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
Supplementary Figure 7. Associations between PIK3R2 gene expression and survival probability amongst TNBC patient cohorts.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
Supplementary Figure 2. Dose de-escalation of the PI3K-mTOR inhibitor, paxalisib, overcomes toxicity burden in combination treatments.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
Supplementary Figure 2. Dose de-escalation of the PI3K-mTOR inhibitor, paxalisib, overcomes toxicity burden in combination treatments.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
Upplementary Table S2. The 23 antibody CODEX panel.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
Upplementary Table S2. The 23 antibody CODEX panel.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
Supplementary Figure 6. EZH2 co-localizes with NF-κB to activate pro-oncogenic gene expression in TNBC.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
Supplementary Figure 6. EZH2 co-localizes with NF-κB to activate pro-oncogenic gene expression in TNBC.